ID: ALA3827609

Max Phase: Preclinical

Molecular Formula: C11H15N2O9P

Molecular Weight: 350.22

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=c1ccn([C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@]23CCO3)c(=O)[nH]1

Standard InChI:  InChI=1S/C11H15N2O9P/c14-7-1-3-13(10(16)12-7)9-11(2-4-20-11)8(15)6(22-9)5-21-23(17,18)19/h1,3,6,8-9,15H,2,4-5H2,(H,12,14,16)(H2,17,18,19)/t6-,8-,9-,11-/m1/s1

Standard InChI Key:  IIGNQSAZLWVQBB-PNHWDRBUSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 350.22

Molecular Weight (Monoisotopic): 350.0515

AlogP: -1.94

#Rotatable Bonds: 4

Polar Surface Area: 160.31

Molecular Species: ACID

HBA: 8

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 11

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 1.22

CX Basic pKa:

CX LogP: -2.08

CX LogD: -5.62

Aromatic Rings: 1

Heavy Atoms: 23

QED Weighted: 0.45

Np Likeness Score: 1.29

References

1. Jonckers TH, Tahri A, Vijgen L, Berke JM, Lachau-Durand S, Stoops B, Snoeys J, Leclercq L, Tambuyzer L, Lin TI, Simmen K, Raboisson P..  (2016)  Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-Cyclic Phosphate Ester Prodrug of 2'-Deoxy-2'-Spirooxetane Uridine Triphosphate Useful for HCV Inhibition.,  59  (12): [PMID:27181575] [10.1021/acs.jmedchem.6b00382]

Source

Source(1):

• Scientific Literature